Announcements Trials

Browse Landscape

Phase

Phase NA 3 Phase 4 3 Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 9 Nausea 5 Breast Neoplasms 4 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Aprepitant × Clear all

NCT01661335 2021-03-23

Efficacy of Aprepitant (Emend®) in Children

University of Oklahoma

Phase 3 Completed

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡